Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer.

[1]  C. Pritchard,et al.  Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery , 2020, British Journal of Cancer.

[2]  D. Timmerman,et al.  Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening , 2019, Nature Cell Biology.

[3]  P. Beale,et al.  Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. , 2019, Gynecologic oncology.

[4]  F. Amant,et al.  Development of Patient-Derived Tumor Xenograft Models. , 2018, Methods in molecular biology.

[5]  C. Moiola,et al.  Patient-Derived Xenograft Models for Endometrial Cancer Research , 2018, International journal of molecular sciences.

[6]  C. Moiola,et al.  Modeling Endometrial Cancer: Past, Present, and Future , 2018, International journal of molecular sciences.

[7]  M. Hashizume,et al.  Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma. , 2018, Cancer letters.

[8]  R. Wenham,et al.  New therapies for advanced, recurrent, and metastatic endometrial cancers , 2017, Gynecologic Oncology Research and Practice.

[9]  Rameen Beroukhim,et al.  Patient-derived xenografts undergo murine-specific tumor evolution , 2017, Nature Genetics.

[10]  Eric C. Huang,et al.  The Use of Endometrial Cancer Patient–Derived Organoid Culture for Drug Sensitivity Testing Is Feasible , 2017, International Journal of Gynecologic Cancer.

[11]  D. Moore,et al.  Ex Vivo Explant Cultures of Non-Small Cell Lung Carcinoma Enable Evaluation of Primary Tumor Responses to Anticancer Therapy. , 2017, Cancer research.

[12]  Bon-Kyoung Koo,et al.  Long-term, hormone-responsive organoid cultures of human endometrium in a chemically-defined medium , 2017, Nature Cell Biology.

[13]  T. Hope,et al.  A microfluidic culture model of the human reproductive tract and 28-day menstrual cycle , 2017, Nature Communications.

[14]  P. Beale,et al.  Phase II study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial—ANZGOG 0903. , 2016 .

[15]  M. Inoue,et al.  Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer , 2016, Cancer science.

[16]  D. Lambrechts,et al.  Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. , 2015, Gynecologic oncology.

[17]  G. Fleming.  Second-Line Therapy for Endometrial Cancer: The Need for Better Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Harikrishna Narasimhan,et al.  Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity , 2015, Nature Communications.

[19]  M. Spector,et al.  Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.

[20]  B. Weigelt,et al.  Classification of endometrial carcinoma: more than two types. , 2014, The Lancet. Oncology.

[21]  Mitsuaki Suzuki,et al.  Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. , 2013, Gynecologic oncology.

[22]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[23]  Joseph M. Negri,et al.  The role of tumour–stromal interactions in modifying drug response: challenges and opportunities , 2013, Nature Reviews Drug Discovery.

[24]  Yong-Man Kim,et al.  Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution. , 2013, Anticancer research.

[25]  D. Miller,et al.  Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study , 2012 .

[26]  Jae-Hyun Park,et al.  Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. , 2012, Cancer cell.

[27]  John J. Evans,et al.  The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer , 2012, Journal of Translational Medicine.

[28]  S. Schwartz,et al.  Generation and characterization of orthotopic murine models for endometrial cancer , 2012, Clinical & Experimental Metastasis.

[29]  A. Bryant,et al.  Adjuvant chemotherapy for endometrial cancer after hysterectomy. , 2011, The Cochrane database of systematic reviews.

[30]  P. Schwartz,et al.  Critical evaluation of human endometrial explants as an ex vivo model system: a molecular approach. , 2011, Molecular human reproduction.

[31]  A. Bryant,et al.  Hormonal therapy in advanced or recurrent endometrial cancer. , 2010, The Cochrane database of systematic reviews.

[32]  K. Moxley,et al.  Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents , 2010, The oncologist.

[33]  R. Casper,et al.  Letrozole stimulates the growth of human endometrial explants cultured in three-dimensional fibrin matrix. , 2009, Fertility and sterility.

[34]  P. Adegboyega,et al.  Immunohistochemical profiling of cytokeratin expression by endometrial stroma sarcoma. , 2008, Human pathology.

[35]  R. Kamps,et al.  Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre- and postmenopausal human endometrium , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[36]  H. Jabbour,et al.  F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. , 2007, Endocrinology.

[37]  G. Fleming,et al.  The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. , 2007, Gynecologic oncology.

[38]  R. Casper,et al.  Expression of Glycodelin and Cyclooxygenase‐2 in Human Endometrial Tissue Following Three‐dimensional Culture , 2007, American journal of reproductive immunology.

[39]  X. Matías-Guiu,et al.  Proteasome Inhibitors Induce Death but Activate NF-κB on Endometrial Carcinoma Cell Lines and Primary Culture Explants* , 2006, Journal of Biological Chemistry.

[40]  Etienne Marbaix,et al.  Response of matrix metalloproteinases and tissue inhibitors of metalloproteinases messenger ribonucleic acids to ovarian steroids in human endometrial explants mimics their gene- and phase-specific differential control in vivo. , 2005, The Journal of clinical endocrinology and metabolism.

[41]  Patrick Neven,et al.  Endometrial cancer , 2005, The Lancet.

[42]  Sung Yeon Kim,et al.  Formation of tamoxifen-DNA adducts in human endometrial explants exposed to α-hydroxytamoxifen , 2005 .

[43]  R. Burger,et al.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Minoti Sharma,et al.  Biotransformation of tamoxifen in a human endometrial explant culture model. , 2003, Chemico-biological interactions.

[45]  Jing Xu,et al.  Three-dimensional in vitro culture of endometrial explants mimics the early stages of endometriosis. , 2003, Fertility and sterility.

[46]  J. Olson,et al.  Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture. , 2003, Biochemical and biophysical research communications.

[47]  V. Brunetto,et al.  Goserelin Acetate as Treatment for Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study , 2002, American journal of clinical oncology.

[48]  K. Osteen,et al.  Effect of TCDD exposure on CYP1A1 and CYP1B1 expression in explant cultures of human endometrium. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[49]  S. Koury,et al.  Expression of AhR and ARNT mRNA in cultured human endometrial explants exposed to TCDD. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[50]  Joan L. Walker,et al.  A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. , 2000, Gynecologic oncology.

[51]  P. Courtoy,et al.  The expression of interstitial collagenase in human endometrium is controlled by progesterone and by oestradiol and is related to menstruation. , 1995, The Biochemical journal.

[52]  D. Decker,et al.  Effects of Progestational Agents in Treatment of Endometrial Carcinoma , 1985, Obstetrics and gynecology.

[53]  John J. Evans,et al.  Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer. , 2013, Experimental cell research.

[54]  F. Landoni,et al.  Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  H. Jabbour,et al.  Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1. , 2010, The American journal of pathology.

[56]  J. Fiorica,et al.  Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.

[57]  A. Stavreus-Evers,et al.  Development and characterization of an endometrial tissue culture system. , 2003, Reproductive biomedicine online.

[58]  R. Schenken,et al.  Whole explants of peritoneum and endometrium: a novel model of the early endometriosis lesion. , 1999, Fertility and sterility.